Spinal muscular atrophy type 2 (SMA type 2) is an inherited disorder that belongs to the spectrum of primary diseases of the anterior horn of the spinal cord. The main cause of SMA is a deficiency of the protein SMN (survival motor neuron), which is necessary for the health and function of motor neurons responsible for muscle movement. This leads to progressive muscle weakness, atrophy, and dysfunction of skeletal muscles. The disease manifests itself in early childhood, and its clinical signs include difficulties in physical development, as well as impaired motor skills, such as sitting and walking. SMA type 2 is characterized by a more favorable course compared to other forms of spinal muscular atrophy, but without timely intervention it can lead to significant limitations in physical activity and deterioration in the quality of life of patients.
History of the disease and interesting historical facts
Spinal muscular atrophy was first described in medical literature in the late 19th century. In 1891, German neurologist Wilhelm Grüntzing proposed the initial classification of muscular atrophy, which later became the basis for understanding the different types of this disease. The first scientific studies concerning the genetic nature of SMA were conducted in the 20th century, when scientists began to study the hereditary patterns of this disease. Interestingly, until recently, SMA was considered a rare disease, but with the development of molecular diagnostics and genetic research, it became clear that it is quite common. For a long time, there were no effective treatments, but in recent years, significant progress has been made in the field of therapy, which allows improving the quality of life of patients with SMA.
Epidemiology
According to various epidemiological studies, the overall prevalence of spinal muscular atrophy is approximately 1 in 6,000–10,000 newborns. There are several types of SMA, each with its own characteristics of the course and prevalence. SMA type 2 is one of the most common forms of this disease. According to statistics, this form of atrophy occurs mainly in children from 6 months to 18 months of life. It is important to note that the disease manifests itself with varying degrees of severity, and not all patients demonstrate a bright clinical picture. Population studies have shown that the frequency of mutations in the SMN1 gene responsible for SMA varies in different ethnic groups. Thanks to new screening methods, it has become possible to detect the disease at earlier stages, which, in turn, can have a positive effect on the prognosis.
Genetic predisposition to this disease
Spinal muscular atrophy type 2 is an autosomal recessive disorder, meaning that two mutant copies of the SMN1 gene are required for the disorder to manifest. At the genetic level, the disorder is caused by mutations in the SMN1 gene, which results in insufficient production of the SMN protein. An important aspect is that most patients with SMA type 2 have a deletion (loss) of one of the SMN1 alleles, while the second allele is usually also defective, but less severe. Deficiency of this protein results in degeneration and death of motor neurons located in the anterior horns of the spinal cord. One of the most important goals of molecular genetics is the early detection of carriers of SMN1 gene pathologies, which can be achieved through genetic testing, especially in families with a history of the disease.
Risk factors for the development of this disease
Spinal muscular atrophy type 2 has a clearly defined genetic cause, and a risk factor is the presence of mutations in the SMN1 gene. While environmental factors do not influence the development of the disease, myths about the influence of irradiation or toxic substances have no scientific basis. However, in some cases, there may be associated genetic conditions that can worsen the symptoms of atrophy. For example:
- Family history of SMA or other neuromuscular disorders.
- Associated mutations in other genes that may worsen the disease.
Children from families with a history of SMA are subject to closer monitoring and may be recommended for genetic counseling.
Diagnosis of this disease
Diagnosis of spinal muscular atrophy type 2 involves a comprehensive approach. The main symptoms of this disease vary and may manifest as the following clinical manifestations:
- Delay in development of motor skills.
- Muscle weakness of a progressive nature.
- Difficulty sitting and walking.
Laboratory tests include:
- Genetic testing for mutations in the SMN1 gene.
- Electromyography, which allows us to assess the function of motor neurons.
Radiological studies are used to rule out other pathologies and may include:
- Magnetic resonance imaging (MRI) to assess the condition of the spinal cord.
Other types of diagnostics:
- Clinical observations and assessment of motor skills.
- Consultations with a neurologist and geneticist.
Differential diagnosis should include other forms of muscular atrophy and neurological diseases such as amyotrophic lateral sclerosis or myotonic dystrophy.
Treatment
Treatment of spinal muscular atrophy type 2 involves a comprehensive approach, including pharmacological, surgical and rehabilitation treatment. In recent years, new therapeutic strategies have been developed, such as:
- Gene therapies (for example, the drug onasemnogene abeparvovec is considered the gold standard).
- Supportive therapy aimed at improving physical activity and functional capabilities.
- Physiotherapy to improve muscle strength and endurance.
Pharmacological treatment includes:
- Drugs that target SMN protein levels, such as nusinersen.
- Supportive therapy to treat associated symptoms such as spasticity.
Surgical treatment may be indicated in cases requiring correction of skeletal deformities or other related orthopedic problems. In addition, it is important to pay attention to nutritional support and psychological assistance to improve the patient's condition.
List of medications used to treat this disease
- Onasemnogene abeparvovec (Zolgensma)
- Nusinersen (Spinraza)
- Respiratory support (if needed)
- Symptomatic treatments for spasticity
Disease monitoring
Monitoring of a patient with SMA type 2 includes regular assessments of respiratory function, motor skills, and general health. Follow-up should be done at least every 6 months, with an emphasis on determining disease progression. Prognosis generally depends on the age of onset of symptoms, the severity of the disease, and the implementation of new therapeutic strategies. Complications may include respiratory infections, which are common in individuals with limited mobility, along with possible orthopedic problems such as scoliosis.
Age-related features of the disease
Spinal muscular atrophy type 2 has its own characteristics of the course depending on the age group. In newborns, symptoms may not appear, but from 6 months onwards, signs of weakness and developmental delays become more obvious. In the group of children over 2 years old, the condition may progress, and the limitation in motor functioning begins to increase. In adolescence and adulthood, later manifestations should be expected, but with the preservation of a significant level of independence. Each age group requires a specific approach to rehabilitation and therapy, with an emphasis on maintaining quality of life and functional abilities.
Questions and Answers
- What is spinal muscular atrophy type 2? It is an inherited disorder caused by a deficiency of the SMN protein, which results in progressive muscle weakness and atrophy.
- What causes spinal muscular atrophy type 2? The underlying cause of the disease is mutations in the SMN1 gene, which results in a deficiency of a protein needed for healthy motor neurons.
- How is SMA type 2 diagnosed? Diagnosis includes genetic testing, observation of symptoms, electromyography and MRI to rule out other diseases.
- What treatments are available for patients with SMA type 2? Various approaches are available, including gene therapies, supportive care, and rehabilitation to improve motor skills.
- What is the prognosis for patients with SMA type 2? The prognosis depends on the age of onset of symptoms and the availability of modern therapeutic interventions that can significantly improve quality of life.
